AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01080989 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: diagnosis, treatment and education
Description: Drug:~anti-intestinal parasitic drugs:~1. mebendazole 500mg one dose (For Hook worm infections, Ascariasis, Trichuriasis)~2. albendazole(400 mg bid \* 7days) or Ivermectin(200 mcg/kg/day \* 2 days) (For Strongyloidiasis).~Behavior:~1. Education capacity building (for local health personals): promote their ability of diagnosis and education to the community and patients for the associated diseases in this study.~2. Assist the trained local health personals to educate the patients and the community from the design of teaching materials and the contents.
Study NCT01093573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone marrow aspiration
Description: Correlative study: Pretreatment bone marrow aspirates or blood \[(3 ml in EDTA tube (purple top)\] will be analyzed according to local institution guidelines to determine whether blasts contain wild type Flt3, ITD, or Flt 3 mutations.
Study NCT03285711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: 200 mg tablet administered orally once daily
Study NCT03285711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib
Description: 30 mg tablet administered orally once daily
Study NCT03285711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib placebo
Description: Tablet administered orally once daily
Study NCT03285711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib placebo
Description: Tablet administered orally once daily
Study NCT03664323 — intervention group
Intervention type: BIOLOGICAL
Intervention: Evaluate the improvement in response from the end of anti-PD-1 monotherapy
Description: Evaluate the improvement in response from the end of anti-PD-1 monotherapy to the first evaluation after introduction of CT alone (Group 1) or combined with anti-PD-1 (Group 2).
Study NCT02800811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FR104
Description: GMP FR104 is provided to the site in extractable volume vials containing FR104. Appropriate Dilutions in Ringer's lactate solution is made on site.
Study NCT05633251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variable (non-random) interval
Description: Using Variable (Non-random) Interval Reinforcement Schedules to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
Study NCT05633251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variable (random) interval with table tents
Description: Using Variable (Random) Interval Reinforcement Schedules and Table Tents with Health-related Messages to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
Study NCT05633251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: No intervention
Study NCT03395340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 1.5% cream
Description: Topical formulation of ruxolitinib, a Janus kinases (JAK) 1/2 inhibitor.
Study NCT03395340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle cream
Description: Matching vehicle cream applied as a thin film
Study NCT02684240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: nitazoxanide 1000 mg orally twice daily with food for 14 days
Study NCT02684240 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The control arm will receive WHO standard therapy for tuberculosis with isoniazid, rifampin, pyrazinamide, and ethambutol
Study NCT01129791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Raw Milk
Description: Organic whole raw cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. for 8 days. After a 1-week wash-out period, pasteurized cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.
Study NCT01129791 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pasteurized Milk
Description: Organic whole pasteurized cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.
Study NCT01129791 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-dairy milk
Description: Unflavored soy milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or pasteurized cow's milk were consumed in the same fashion for another 8 days each.
Study NCT03416582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Management Education and Nurse Coaching
Description: The registered nurse (RN) will teach good mouth care and management of sore mouth or throat (mucositis) symptoms to the patient for self-management at home. The RN will then call the patient twice every week to continue educating and coaching the patient about the mucositis self-management. The patient will receive the Symptom Management (SxM) Toolkit which is a written educational guide known as the Cancer Treatment Symptom Management Education Toolkit geared to help the patient manage their symptoms of sore mouth and throat at home in order to prevent dehydration.
Study NCT03416582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drinks Diary
Description: The patient will complete the Drinks Diary daily by recording the all oral fluid ingested and also record the number of times the bathroom is used.
Study NCT02434315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Pro 4 sensor wears, 2 with reviews
Description: Subjects will wear the FreeStyle Libre Pro System for 14 days. 2 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
Study NCT02434315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Pro 6 sensor wears, 4 with reviews
Description: Subjects will wear the FreeStyle Libre Pro System for 14 days. 4 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
Study NCT02434315 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FreeStyle Libre Pro 3 sensor wears
Description: Subjects will wear the FreeStyle Libre Pro System for 14 days. 3 periods of Sensor wear for time in range measurement over a period of approximately 8 months.
Study NCT04072237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MarzAA (marzeptacog alfa [activated])
Description: Single intravenous dose and ascending doses of subcutaneous injection of MarzAA (Coagulation Faction VIIa Variant)
Study NCT01102660 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PH-797804
Description: Tablet, 6 mg once daily for 2 weeks
Study NCT01102660 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Tablet, 0 mg once daily for 2 weeks
Study NCT02369406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Study NCT02369406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra
Study NCT02384499 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASC injection
Description: Allogenic-adipose-derived mesenchymal stem cells (ALLO-ASC) injection to the anal sphincter of patients with fecal incontinence
Study NCT02384499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% normal saline with fibrin glue injection to the anal sphincter of patients with fecal incontinence
Study NCT02800811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo injection contains the vehicle. For placebo dosing, vehicle is administered in accordance with the volume of study drug administered.
Study NCT03328559 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ISET® - Isolation by Size of Tumor cells
Description: early stage bronchial cancer patient will have a blood collection
Study NCT02942550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylnaltrexone bromide (Relistor®).
Study NCT02942550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9mg/mL
Study NCT05447130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification
Description: phacoemulsification with corneal endothelial evaluation by specular microscopy
Study NCT02629497 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Primrose oil
Description: T2DM patients and matched controls subjects will be given Primrose oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
Study NCT02369406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Study NCT02629497 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: T2DM patients and matched controls subjects will be given Fish oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
Study NCT02369406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Study NCT03643744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: 14 Celecoxib 200mg taken 1 in the morning and 1 in the evening.
Study NCT03328559 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ISET® - Isolation by Size of Tumor cells
Description: advanced stage bronchial cancer patient will have a blood collection
Study NCT00886132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 37.5 mg taken orally, daily every 28-day cycles
Study NCT02022683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELVR (Endoscopic Lung Volume Reduction) with Zephyr Valves
Study NCT00504166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alendronate sodium
Description: alendronate sodium 70 mg tablet once week for 24 months
Study NCT00504166 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: placebo to match alendronate sodium one tablet once a week for 24 months
Study NCT04379804 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral approach
Description: Following the ligation of upper pole vessels, the thyroid lobe was pulled anteromedially and the RLN was dissected within the carotid triangle at the level of inferior thyroid artery (ITA).
Study NCT04379804 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cranio-caudal approach
Description: Following the ligation of upper pole vessels, the upper pole was retracted antero-medially to expose crico-pharyngeal muscle. The RLN was identified at the point of entry both visually and with hand held stimulation probe
Study NCT02078622 — intervention group
Intervention type: OTHER
Intervention: Respiratory Therapist Education and Case Management
Description: Respiratory Therapists will conduct home care visits over a period of one-year at two-week intervals
Study NCT01345786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Commercial NOMAC-E2
Description: 1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination commercial tablet orally in the morning on Day 1 for all periods
Study NCT01102660 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Naproxen
Description: Tablet, 500 mg twice daily for 2 weeks
Study NCT01102660 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Naproxen + PH-797804
Description: Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
Study NCT03643744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 14 placebo capsules taken 1 in the morning and 1 in the evening.
Study NCT00884390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moroctocog alfa (AF-CC) (ReFacto AF)
Description: Providing moroctocog alfa (AF-CC) as test article for use during this study.
Study NCT00884390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laboratory tests
Description: Laboratory samples are collected during study visits, in order to collect safety and efficacy data related to the administration of test article.
Study NCT02050165 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KIND Bars
Description: Consumption of KIND Bars for 12 weeks
Study NCT02050165 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Typical American Snack
Description: Consumption of typical American snacks for 12 weeks
Study NCT03102385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: A web-based computer-tailored intervention that includes open-ended questions, reflective responses, affirmations, and summarizing, as well as informing and advising. Specific topics include 1) individual motivations for giving, 2) the relationship between past donation behavior and the individual's personal goals/values, 3) donation importance and confidence rulers, 4) addressing donor concerns, and 5) summarizing.
Study NCT03102385 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Knowledge Interview
Description: A web-based interview that includes open-ended questions regarding blood donation knowledge.
Study NCT00702507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25 % Miconazole Nitrate Ointment
Description: Topical Application
Study NCT03755596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z. officinale extract
Description: Oral dose of 160mg dry ginger root (Z. officinale) extract in tablet form.
Study NCT02571257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: 1-300 mg tablet, QD, 56 days
Study NCT02571257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: 3-300 mg tablets, QD, 56 days
Study NCT02571257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00564031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femanest
Description: 2mg/day
Study NCT04114396 — intervention group
Intervention type: DRUG
Intervention: Anti-IL5 Antibody
Description: Asthma group: Anti-IL5 treatment Control group: No biologic.
Study NCT04114396 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Optional for both arms
Study NCT02528955 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: A: De-Intensification RT primary tumor region
Description: A:~* Reduction of radiation dose in the primary tumor region to 56 Gy,~* Elective Radiotherapy of both neck sides
Study NCT02528955 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: B: De-Intensification RT contralateral lymph nodes
Description: B:~* No dose reduction in primary tumor region (prescribed dose in primary tumor region: 64 Gy)~* Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no contralateral neck irradiation
Study NCT01345786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phase 3 NOMAC-E2 Batch A
Description: 1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch A) orally in the morning on Day 1 for all periods
Study NCT02528955 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: C. De-Intensification RT primary tumor region AND contralateral lymph nodes
Description: C:~* Reduction of radiation dose in the primary tumor region to 56 Gy, AND~* Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no contralateral neck irradiation
Study NCT01345786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phase 3 NOMAC-E2 Batch B
Description: 1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch B) orally in the morning on Day 1 for all periods
Study NCT01870609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: defactinib (VS-6063)
Study NCT01870609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic defactinib tablet
Study NCT02521064 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Exclusive Enteral Nutrition (EEN)
Description: Patients will be treated with 8 weeks of Exclusive Enteral Nutrition (EEN). Patients will continue to receive usual medical care, and concurrent IBD treatments will be permitted.
Study NCT02521064 — intervention group
Intervention type: DRUG
Intervention: Prednisone
Description: Patients will be treated with 8 weeks of prednisone (corticosteroid). Patients will continue to receive usual medical care, and concurrent IBD treatments will be permitted.
Study NCT02422043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires and audio-tape interviews
Description: therapeutic patient education programs (TPE) to type 1 diabetic adolescents are designed to make the teenager to self manage their disease and their treatment. Based on Bandura's social cognitive theory, effects of educational activities for TPE should lead to the strengthening of self-efficacy
Study NCT03268746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof IQ PanOptix Multifocal IOL
Description: AcrySof IQ PanOptix Multifocal IOL Model TFNT00 for near, intermediate, and distance vision intended for long-term use over the lifetime of the cataract subject
Study NCT05393583 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Outpatient hysterectomy
Description: Discharge on the day of the hysterectomy
Study NCT05393583 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient hysterectomy
Description: 1 night hospital stay after hysterectomy
Study NCT05518344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viziatek ISL™ (hereinafter referred to as the ISL) implanted in blind eye.
Description: Viziatek ISL™ (hereinafter referred to as the ISL) implanted in blind eye.
Study NCT04495361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-learning portal
Description: An online learning portal for the identification and management of pneumonia in under five children
Study NCT02140918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone 100 μg
Description: Fludrocortisone 100 μg/day
Study NCT02140918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone 200 μg
Description: Fludrocortisone 200 μg/day
Study NCT02140918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone 400 μg
Description: Fludrocortisone 400 μg/day
Study NCT02140918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02219594 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CT image for patient with suspected in-stent restenosis
Description: Gemstone CT or 320-detector row spiral CT was assigned randomly to patient who was suspected in-stent restenosis.About after 10 days,they would accept the check of OCT which wold be the gold standard of in-stent restenosis.
Study NCT02219594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT image for patient with suspected in-stent restenosis
Description: Gemstone CT or 320-detector row spiral CT was assigned randomly to patient who was suspected in-stent restenosis.About after 10 days,they would accept the check of OCT which wold be the gold standard of in-stent restenosis.
Study NCT03656016 — intervention group
Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Phase contrast magnetic resonance imaging technique
Study NCT00109733 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone
Description: 0.005 mg/kg/day for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.
Study NCT03251378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib (HMPL-013)
Description: Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class.
Study NCT02374086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Study NCT03524079 — intervention group
Intervention type: DRUG
Intervention: Ajmaline 17-(Chloroacetate) Monohydrochloride
Description: Ajmaline 17-(Chloroacetate) Monohydrochloride(1mg/kg in 5 minutes)
Study NCT00109733 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone
Description: 0.010 mg/kg/day for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.
Study NCT01263535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish
Description: Contact lens-based device for the continuous recording of IOP fluctuations, with a portable recording system
Study NCT04365816 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: A survey was created, aiming to collect information about prior history of chronic disease, the Self-Evaluation of Food Intake, dysregulations (anosmia, ageusia...), anthropometric data, food data during and after hospitalisation, healthcare consumption since the discharge from hospital
Study NCT01090037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-100STP high dose